PDCD1 and neoplasm: In recent analyses of recurrent GBM patients that were treated with PD-1 immune checkpoint blockade, we showed that mitogen-activated protein kinase (MAPK) signaling activation in tumor cells was associated with response to this therapy21,22 highlighting the role of tumor kinases in immune modulation.